
FDA Voucher Program Reportedly Shelved: What Sponsors Face Now
Reuters reports FDA has shelved its national priority voucher pilot; HHS says it is ongoing. What 22 voucher holders and nine pending reviews face now.
Coverage of early-stage science, platform technologies, R&D innovation, and emerging companies shaping the future of medicine. From discovery breakthroughs to financing rounds and pipeline progress, this section tracks the momentum driving the biotech ecosystem.

Reuters reports FDA has shelved its national priority voucher pilot; HHS says it is ongoing. What 22 voucher holders and nine pending reviews face now.

The Pentagon removed WuXi AppTec from its Section 1260H list after a court injunction. Here is what changes for sponsors, and what BIOSECURE still could do.

How earnouts, contingent value rights, milestones and royalties work in biotech and medtech deals, with a worked example and a checklist for buyers and sellers.

Subcutaneous versions of IV biologics like Keytruda, Opdivo and Rybrevant now take minutes to give. Here is how hyaluronidase co formulation works.

How long FDA expects gene therapy patients to be followed, why AAV gets up to five years and integrating vectors 15, and what Zolgensma’s tumor reports change.

The science works. The manufacturing doesn’t scale. That is the central tension in cell and gene therapy right now. More than 3,000 cell and gene

More than 200 AI-designed drugs are now in clinical development. Phase I success rates for AI-discovered compounds are running between 80% and 90%, roughly double

Every breakthrough drug has an invisible army behind it. Not just the scientists in lab coats or the executives signing deals — but the platforms,

What Is a Biomarker: Modern medicine runs on measurement. Before treating a disease, you need to detect it. Before knowing if a drug works, you

Every week, billions of dollars shift in biotech based on a handful of pivotal moments: FDA decisions, clinical trial readouts, earnings calls, and conference presentations.